Coverage
-
July 16, 2015
The whistleblower who alerted the government to Endo Pharmaceuticals Inc.'s off-label marketing of the pain-relief patch Lidoderm won 24 percent of a $140 million False Claims Act settlement Wednesday, with a Pennsylvania federal judge rejecting the government's argument she deserved only 19 percent.
1 other articles on this case.
View all »